Last reviewed · How we verify
Palifermin before and after
Palifermin is a keratinocyte growth factor (KGF) receptor agonist that stimulates epithelial cell proliferation and differentiation to protect and repair oral mucosa.
Palifermin is a keratinocyte growth factor (KGF) receptor agonist that stimulates epithelial cell proliferation and differentiation to protect and repair oral mucosa. Used for Chemotherapy-induced oral mucositis in patients receiving myeloablative chemotherapy followed by hematopoietic stem cell transplantation.
At a glance
| Generic name | Palifermin before and after |
|---|---|
| Also known as | Kepivance |
| Sponsor | Swedish Orphan Biovitrum |
| Drug class | Keratinocyte growth factor (KGF) receptor agonist |
| Target | FGFR2 (Fibroblast Growth Factor Receptor 2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Palifermin binds to and activates the fibroblast growth factor receptor 2 (FGFR2), which is expressed on epithelial cells lining the oral cavity and gastrointestinal tract. This activation promotes cell proliferation, differentiation, and migration, enhancing the protective barrier function of the mucosa and reducing the severity and duration of chemotherapy-induced oral mucositis.
Approved indications
- Chemotherapy-induced oral mucositis in patients receiving myeloablative chemotherapy followed by hematopoietic stem cell transplantation
Common side effects
- Dysgeusia (altered taste)
- Mouth/tongue thickness
- Rash
- Edema
Key clinical trials
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (PHASE1, PHASE2)
- Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study (PHASE1, PHASE2)
- Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease (PHASE1, PHASE2)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy (PHASE1, PHASE2)
- Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (PHASE2)
- Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
- Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Palifermin before and after CI brief — competitive landscape report
- Palifermin before and after updates RSS · CI watch RSS
- Swedish Orphan Biovitrum portfolio CI